中源协和：公司将持续推进干细胞新药研发

Core Viewpoint - The company, Zhongyuan Xiehe (600645), is committed to advancing stem cell drug research and development, enhancing its R&D system, and deepening collaborations with top-tier hospitals and research institutions to establish a robust R&D technology platform [1] Group 1: R&D Strategy - The company will continue to enrich and expand its R&D pipeline, accelerating the transformation and market promotion of new products [1] - The focus will be on both domestic market development and proactive international market positioning [1] Group 2: Collaboration and Partnerships - The company aims to promote the development of cell therapy business through diversified collaboration models [1]